Novartis’ position as the frontrunner in the race to bring a Tim3-targeting drug to market has been lost after it pulled a phase 3 trial of its sabatolimab candidate.
After disappointing results in other indications, AnaptysBio has a route to market with its IL-36 receptor inhibitor imsidolimab in a rare and life-threatening form of the
Less than three years after being spun out of Oxford University, privately-held biotech MiroBio is heading for a takeover by Gilead Sciences in a $405 million deal.
Astellas has added another gene therapy to its pipeline, taking an option on a clinical-stage candidate for a rare genetic form of dementia from UK biotech AviadoBio for around $50 million.